Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

Human Gene Therapy

Volumn 10, Issue 4, 1999, Pages 649-657

  Puhlmann, Markus ^a   Gnant, Michael ^a   Brown, Charles K ^a   Alexander, H Richard ^a   Bartlett, David L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLPURINE; 6MPDR; CYTOSINE DEAMINASE; DEOXYRIBOSE; PRODRUG; PSORALEN; PURINE; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DELETION MUTANT; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; SURVIVAL TIME; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; CELL SURVIVAL; GENE DELETION; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASMS; PSORALENS; PURINE-NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; TUMOR CELLS, CULTURED; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; MUS MUSCULUS; VACCINIA; VACCINIA VIRUS;

EID: 0033105882     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018724     Document Type: Article

References (18)

1. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376. [See comments].
2. BRONTE, V., TSUNG, K., RAO, J.B., CHEN, P.W., WANG, M., ROSENBERG, S.A., and RESTIFO, N.P. (1995). IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154, 5282-5292.
3. BULLER, R.M., SMITH, G.L., CREMER, K., NOTKINS, A.L., and MOSS, B. (1985). Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (London) 317, 813-815.
4. CHAISOMCHIT, S., TYRRELL. D.J., AND CHANG, L.J. (1997). Development of replicative and nonreplicative hepatitis B virus vectors. Gene Ther. 4, 1330-1340.
5. DACHS, G.U., DOUGHERTY, G.J., STRATFORD, I.J., and CHAPLIN, D.J. (1997). Targeting gene therapy to cancer: A review. Oncol. Res. 9, 313-325.
6. DAVISON, A.J., and MOSS, B. (1989a). Structure of vaccinia virus early promoters. J. Mol. Biol. 210, 749-769.
7. DAVISON, A.J., and MOSS, B. (1989b). Structure of vaccinia virus late promoters. J. Mol. Biol. 210, 771-784.
8. EARL, P.L., and MOSS, B. (1991). Expression of proteins in mammalian cells using vaccinia viral vectors. In Current Protocols in Molecular Biology. P.M. Ausubel, R. Kinston, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl, eds. (Greene/Wiley Interscience, New York), pp. 16.15.1-16.18.10.
9. HUGHES, B.W., WELLS, A.H., BEBOK, Z., GADI, V.K., CARVER, R.I., JR., PARKER, W.B., and SORSCHER, E.J. (1995). Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55, 3339-3345.
10. IRVINE, K.R., McCABE, B.J., ROSENBERG, S.A., and RESTIFO, N.P. (1995). Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 154, 4651-4657.
11. MOSS, B. (1991). Vaccinia virus: A tool for research and vaccine development. Science 252, 1662-1667.
12. NESTLER, U., HEINKELEIN, M., LÜCKE, M., MEIXENSBERGER, J., SCHEURLEN, W., KRETSCHMER, A., and RETHWILM, A. (1997). Foamy virus vectors for suicide gene therapy. Gene Ther. 4, 1270-1277.
13. PARKER, W.B., KING, S.A., ALLAN, P.W., BENNETT, L.L., JR., SECRIST, J.A., MONTGOMERY, J.A., GILBERT, K.W., WAUD, W.R., WELLS, A.H., GILLESPIE, G.Y., and SORSCHER, E.J. (1997). In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. 8, 1637-1644.
14. PEPLINSKI, G.R., TSUNG, K., CASEY, M.J., MEKO, J.B., FREDRICKSON, T.N., BULLER, R.M.L., and NORTON, J.A. (1996). In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta. Cancer J. 2, 21-27.
15. PUHLMANN, M., BROWN, C.K., GNANT, M., HUANG, J. LIBUTTI, S.K., ALEXANDER, H.R., and BARTLETT, D.L. (1999). Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther. (in press).
16. SORSCHER, E.J., PENG, S., BEBOK, Z., ALLAN, P.W., BENNETT, L.L., and PARKER, W.B. (1994). Tumor cell bystander killing in colonie carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1, 233-238.
17. TSUNG, K., YIM, J.H., MARI, W., BULLER, R.M.L., and NORTON, J.A. (1996). Gene expression and cytopathic effect of chemically inactivated vaccinia virus. J. Virol. 70, 165-171.
18. WHITMAN, E.D., TSUNG, K., PAXSON, J., and NORTON, J.A. (1994). In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 116, 183-188.